Profile banner
Niamh Troy

Niamh Troy

Manager, External Partnering and translational immunology

Dublin, Ireland
theorg+1
Favicon imagetheconversation.com
Favicon imagescholar.google.com
Favicon imageresearch-repository.uwa.edu.au

Summary

Systems immunology researcher focused on infant innate immunity and asthma prevention. Her PhD and subsequent postdoctoral work used systems biology and gene network approaches to study how early-life immune responses and microbial exposures influence risk of severe respiratory infections and later asthma; she has contributed to studies of OM85 immune training and airway microbiome dynamics. edu+2
Translational and industry-engaged professional who moved from academic research into medical device innovation and business development. She took roles in innovation, engagement and business development at OncoRes Medical and is listed in an external partnering manager role at Eli Lilly, indicating a shift toward external partnering and commercial translation of biomedical technologies. oncoresmedical+2
Recognized early-career scientist actively involved in public communication and outreach. She was a joint winner of the ExxonMobil WA Premier's Student Scientist of the Year award (2021), has written accessible explainers about her research, and regularly participates in community science engagement. org+2
Collaborative author with an established publication record across high-impact, multi-author studies in pediatric respiratory research. Her authorship on studies of the infant airway microbiome, epithelial models and immune-modulatory interventions reflects both laboratory and computational/systems-biology contributions. nih+2

Work

Education

Projects

Writing

We boosted babies’ immune systems and it protected them from serious lung infections: new research

February 1, 2022

A lay-facing explainer (The Conversation) summarizing research findings on how OM85 trains infant innate immunity to reduce severity of lung infections and potential implications for asthma prevention.

Favicon imagetheconversation.com

Primary prevention of severe lower respiratory illnesses in at-risk infants using the immunomodulator OM-85

January 1, 2019

Randomized controlled trial and report on the use of the bacterial-derived immunomodulator OM85 to reduce severe lower respiratory illnesses in at-risk infants.

Favicon imagepubmed.ncbi.nlm.nih.gov

Airway Microbiota Dynamics Uncover a Critical Window for Interplay of Pathogenic Bacteria and Allergy in Childhood Respiratory Disease

January 1, 2018

Multi-author research article characterizing nasopharyngeal microbiome dynamics in infants and linking bacterial colonization and early allergic sensitization with persistent wheeze and asthma risk.

Favicon imagepubmed.ncbi.nlm.nih.gov

A differentiated nasal epithelial cell model derived from children with acute wheeze and asthma

Work establishing an in vitro differentiated nasal epithelial model from children with acute wheeze/asthma to investigate epithelial vulnerabilities and responses relevant to pathogen infection and disease mechanisms.

Favicon imageresearch-repository.uwa.edu.au

Hobbies

Science communication and community STEM outreach, including public engagement activities. nitter+1